U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H22O3
Molecular Weight 310.3869
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AVOBENZONE

SMILES

COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C

InChI

InChIKey=XNEFYCZVKIDDMS-UHFFFAOYSA-N
InChI=1S/C20H22O3/c1-20(2,3)16-9-5-14(6-10-16)18(21)13-19(22)15-7-11-17(23-4)12-8-15/h5-12H,13H2,1-4H3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.wikidoc.org/index.php/Avobenzone | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3fd7fb-4a28-4db8-9a4d-d7fdd2e45daf

Avobenzone is an oil soluble ingredient used in sunscreen products to absorb the full spectrum of UVA rays. It helps prevent sunburn. Avobenzone works by absorbing the rays and converting them to energy that is less damaging to the skin.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
SHADE UVAGUARD

Approved Use

helps prevent sunburn; higher SPF gives more sunburn protection; helps provide protection from UVA rays (short and long wavelengths).

Launch Date

7.2368639E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.5 ng/mL
0.81 g 4 times / day multiple, topical
dose: 0.81 g
route of administration: Topical
experiment type: MULTIPLE
co-administered:
AVOBENZONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.1 ng/mL
0.81 g 4 times / day steady-state, topical
dose: 0.81 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
AVOBENZONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
45.2 h
0.81 g 4 times / day steady-state, topical
dose: 0.81 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
AVOBENZONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3.7 g 1.3 times / day multiple, topical (median)
Recommended
Dose: 3.7 g, 1.3 times / day
Route: topical
Route: multiple
Dose: 3.7 g, 1.3 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 3.69 years (range: 0.64-48.15 years)
n = 79
Health Status: healthy
Age Group: 3.69 years (range: 0.64-48.15 years)
Sex: M+F
Population Size: 79
Sources:
Other AEs: Dermatitis, Eczema...
Other AEs:
Dermatitis (2.5%)
Eczema (1.3%)
Sources:
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
Other AEs: Acne, Dermatitis...
Other AEs:
Acne (4.8%)
Dermatitis (2.8%)
Dry skin (1.2%)
Eczema (1.2%)
Erythema (1.2%)
Pruritus (2%)
Rosacea (0.4%)
Seborrhea (0.8%)
Skin discomfort (1.2%)
Sunburn (0.8%)
Conjunctivitis (0.8%)
Taste perversion (0.4%)
Sources:
3.1 g 1.2 times / day multiple, topical (median)
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 6.69 years (range: 0.5-67.95 years)
n = 246
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Population Size: 246
Sources:
Other AEs: Dermatitis, Eczema...
Other AEs:
Dermatitis (2.8%)
Eczema (0.4%)
Erythema (0.8%)
Skin discomfort (0.8%)
Sunburn (1.6%)
Conjunctivitis (0.4%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Eczema 1.3%
3.7 g 1.3 times / day multiple, topical (median)
Recommended
Dose: 3.7 g, 1.3 times / day
Route: topical
Route: multiple
Dose: 3.7 g, 1.3 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 3.69 years (range: 0.64-48.15 years)
n = 79
Health Status: healthy
Age Group: 3.69 years (range: 0.64-48.15 years)
Sex: M+F
Population Size: 79
Sources:
Dermatitis 2.5%
3.7 g 1.3 times / day multiple, topical (median)
Recommended
Dose: 3.7 g, 1.3 times / day
Route: topical
Route: multiple
Dose: 3.7 g, 1.3 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 3.69 years (range: 0.64-48.15 years)
n = 79
Health Status: healthy
Age Group: 3.69 years (range: 0.64-48.15 years)
Sex: M+F
Population Size: 79
Sources:
Rosacea 0.4%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
Taste perversion 0.4%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
Conjunctivitis 0.8%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
Seborrhea 0.8%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
Sunburn 0.8%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
Dry skin 1.2%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
Eczema 1.2%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
Erythema 1.2%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
Skin discomfort 1.2%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
Pruritus 2%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
Dermatitis 2.8%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
Acne 4.8%
1.6 g 1.1 times / day multiple, topical (median)
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 35.44 years (range: 12.04-83.43 years)
n = 248
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Population Size: 248
Sources:
Conjunctivitis 0.4%
3.1 g 1.2 times / day multiple, topical (median)
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 6.69 years (range: 0.5-67.95 years)
n = 246
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Population Size: 246
Sources:
Eczema 0.4%
3.1 g 1.2 times / day multiple, topical (median)
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 6.69 years (range: 0.5-67.95 years)
n = 246
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Population Size: 246
Sources:
Erythema 0.8%
3.1 g 1.2 times / day multiple, topical (median)
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 6.69 years (range: 0.5-67.95 years)
n = 246
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Population Size: 246
Sources:
Skin discomfort 0.8%
3.1 g 1.2 times / day multiple, topical (median)
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 6.69 years (range: 0.5-67.95 years)
n = 246
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Population Size: 246
Sources:
Sunburn 1.6%
3.1 g 1.2 times / day multiple, topical (median)
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 6.69 years (range: 0.5-67.95 years)
n = 246
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Population Size: 246
Sources:
Dermatitis 2.8%
3.1 g 1.2 times / day multiple, topical (median)
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Co-administed with::
ecamsule
octocrylene
titanium dioxide
Sources:
healthy, 6.69 years (range: 0.5-67.95 years)
n = 246
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Population Size: 246
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as perpetrator​
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Multiple chemical sensitivities, including iatrogenic allergic contact dermatitis, in a patient with chronic actinic dermatitis: implications for management.
1996 Sep
Photochemical studies of 4-tert-butyl-4'-methoxydibenzoylmethane (BM-DBM).
2001 Nov 15
Photostabilization of butyl methoxydibenzoylmethane (Avobenzone) and ethylhexyl methoxycinnamate by bis-ethylhexyloxyphenol methoxyphenyl triazine (Tinosorb S), a new UV broadband filter.
2001 Sep
The effect of UV absorbing sunscreens on the reflectance and the consequent protection of skin.
2002 Feb
A new model using liposomes that allow to distinguish between absorption and oxidative properties of sunscreens.
2002 Jan
The effects of derivatives of the nitroxide tempol on UVA-mediated in vitro lipid and protein oxidation.
2002 Jul 1
Protection against UVB irradiation by natural filters extracted from lichens.
2002 Nov
Non-invasive in vivo determination of UVA efficacy of sunscreens using diffuse reflectance spectroscopy.
2003 Aug
Bioconvertible vitamin antioxidants improve sunscreen photoprotection against UV-induced reactive oxygen species.
2003 Nov-Dec
Lack of in vitro protection by a common sunscreen ingredient on UVA-induced cytotoxicity in keratinocytes.
2004 Oct 15
Determination of sixteen UV filters in suncare formulations by high-performance liquid chromatography.
2004 Sep 17
Photochemical behavior of a new long-chain UV absorber derived from 4-tert-butyl-4'-methoxydibenzoylmethane.
2004 Sep-Oct
Interaction of polycyclic musks and UV filters with the estrogen receptor (ER), androgen receptor (AR), and progesterone receptor (PR) in reporter gene bioassays.
2005 Feb
Sunscreen penetration of human skin and related keratinocyte toxicity after topical application.
2005 Jul-Aug
A new long-chain UV absorber derived from 4-tert-butyl-4'-methoxydibenzoylmethane: absorbance stability under solar irradiation.
2005 Mar-Apr
Unexpected photolysis of the sunscreen octinoxate in the presence of the sunscreen avobenzone.
2005 Mar-Apr
Sun protection strength of a hydroquinone 4%/retinol 0.3% preparation containing sunscreens.
2006 Apr
Evaluation of the photostability of different UV filter combinations in a sunscreen.
2006 Jan 13
Changes in ultraviolet absorbance and hence in protective efficacy against lipid peroxidation of organic sunscreens after UVA irradiation.
2006 Mar 1
Design of a photostabilizer having built-in antioxidant functionality and its utility in obtaining broad-spectrum sunscreen formulations.
2006 May-Jun
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods.
2006 Nov
Interactions between different solar UVB/UVA filters contained in commercial suncreams and consequent loss of UV protection.
2006 Sep
The FDA approves new over-the-counter sunscreen.
2006 Sep-Oct
I've heard there's a new sunscreen that's supposed to offer better skin protection. Can you tell me more?
2007 Jun
A new sunscreen agent.
2007 May 21
Transient enol isomers of dibenzoylmethane and avobenzone as efficient hydrogen donors toward a nitroxide pre-fluorescent probe.
2007 May-Jun
Degradation kinetics of butylmethoxydibenzoylmethane (avobenzone) in aqueous solution.
2007 Oct
In vitro assessments of UVA protection by popular sunscreens available in the United States.
2008 Dec
Impact on facial rejuvenation with dermatological preparations.
2009
Role of UV light in photodamage, skin aging, and skin cancer: importance of photoprotection.
2009
Optical and electron paramagnetic resonance studies of the excited states of 4-tert-butyl-4'-methoxydibenzoylmethane and 4-tert-butyl-4'-methoxydibenzoylpropane.
2009 Dec 3
A blocked diketo form of avobenzone: photostability, photosensitizing properties and triplet quenching by a triazine-derived UVB-filter.
2009 Jan-Feb
Photodegradation of dibenzoylmethanes: potential cause of photocontact allergy to sunscreens.
2009 Nov
Filter-filter interactions. Photostabilization, triplet quenching and reactivity with singlet oxygen.
2010 Apr
Characterization of the UVA protection provided by avobenzone, zinc oxide, and titanium dioxide in broad-spectrum sunscreen products.
2010 Dec 1
Polymorphism and reversible mechanochromic luminescence for solid-state difluoroboron avobenzone.
2010 Feb 24
True photoallergy to sunscreens is rare despite popular belief.
2010 Jul-Aug
A randomized, controlled comparative study of the wrinkle reduction benefits of a cosmetic niacinamide/peptide/retinyl propionate product regimen vs. a prescription 0.02% tretinoin product regimen.
2010 Mar
An Assessment of the Efficacy and Safety of CROSS Technique with 100% TCA in the Management of Ice Pick Acne Scars.
2010 May
Determination of organic UV filters in water by stir bar sorptive extraction and direct analysis in real-time mass spectrometry.
2010 May
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.
2013 Sep 5
Chemical allergens stimulate human epidermal keratinocytes to produce lymphangiogenic vascular endothelial growth factor.
2015 Mar 1
Patents

Sample Use Guides

apply liberally 15 min before sun exposure. reapply as needed or after towel drying, 40 min of swimming, or perspiring.
Route of Administration: Topical
In Vitro Use Guide
Sources: DOI: 10.7324/JAPS.2015.50611
Avobenzone 2% and ethyl ascorbic acid2% represented the best photostability with avobenzone concentrations decrease by 11,82% for 15 hour using UVA lamp irradiation 4,7 mW/cm2.
Name Type Language
AVOBENZONE
HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
NEOHELIOPAN 357
Brand Name English
AVOBENZONE [USP-RS]
Common Name English
Avobenzone [WHO-DD]
Common Name English
NSC-758680
Code English
AVOBENZONE COMPONENT OF ANTHELIOS SX
Common Name English
AVOBENZONE COMPONENT OF SHADE UVAGUARD
Common Name English
1,3-PROPANEDIONE, 1-(4-(1,1-DIMETHYLETHYL)PHENYL)-3-(4-METHOXYPHENYL)-
Systematic Name English
ESCALOL 517
Brand Name English
4-METHOXY-4'-TERT-BUTYLDIBENZOYLMETHANE
Common Name English
BUTYL METHOXYDIBENZOYLMETHANE [INCI]
Common Name English
1-(4-TERT-BUTYLPHENYL)-3-(4-METHOXYPHENYL)PROPAN-1,3-DIONE
Systematic Name English
BUTYL METHOXYDIBENZOYLMETHANE
INCI  
INCI  
Official Name English
AVOBENZONE [MART.]
Common Name English
AVOBENZONE [USP IMPURITY]
Common Name English
AVOBENZONE [MI]
Common Name English
AVOBENZONE [HSDB]
Common Name English
CAPITAL SOLEIL COMPONENT AVOBENZONE
Common Name English
ANTHELIOS SX COMPONENT AVOBENZONE
Common Name English
avobenzone [INN]
Common Name English
EUSOLEX 9020
Brand Name English
AVOBENZONE [ORANGE BOOK]
Common Name English
AVOBENZONE [USP MONOGRAPH]
Common Name English
AVOBENZONE COMPONENT OF CAPITAL SOLEIL
Common Name English
AVOBENZONE [USAN]
Common Name English
PARSOL 1789
Brand Name English
SHADE UVAGUARD COMPONENT AVOBENZONE
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 142401
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
NCI_THESAURUS C851
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
CFR 21 CFR 352.10
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
Code System Code Type Description
EVMPD
SUB05617MIG
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
RXCUI
45045
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY RxNorm
USAN
AA-89
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
WIKIPEDIA
AVOBENZONE
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
INN
6480
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
FDA UNII
G63QQF2NOX
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
PUBCHEM
51040
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
ChEMBL
CHEMBL1200522
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
EPA CompTox
DTXSID9044829
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
HSDB
7423
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
DAILYMED
G63QQF2NOX
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
ECHA (EC/EINECS)
274-581-6
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
MERCK INDEX
m2151
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY Merck Index
RS_ITEM_NUM
1045337
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
NCI_THESAURUS
C47406
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
NSC
758680
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
DRUG CENTRAL
4242
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
CAS
70356-09-1
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
DRUG BANK
DB09495
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY
SMS_ID
100000086882
Created by admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
PRIMARY